1 Sun BJ, Wang Q, Lu JX, et al. The related factors of depression after first episode stroke. Med Forum Mag, 2008, 29 (3): 75-6.
2 Affan M, Shaikh Q, Kamal AK. Should I prevent my patient from developing depression after stroke? What is the best available option? J Pak Med Assoc, 2014, 64(5): 603.
3 Mikami K, Jorge RE, Moser DJ, et al. Increased frequency of first-episode poststroke depression after discontinuation of escitalopram. Stroke. 2011, 42(11): 3281-3.
4 Paolucei S. Epidemiology and treatment of post-stroke depression. Neuropsy Dis and Treatment, 2008, 4(1): 145-54.
5 Kotila M, Numminen H, Waltimo O, et al. Depression after stroke: results of the finnstroke study. Stroke, 1998, 29: 368-72.
6 Yan Y, Fan W, Liu L, et al. The effects of Xingnao Jieyu capsules on post-stroke depression are similar to those offluoxetine. Neural Regen Res, 2013, 8(19): 1765-72.
7 Li LT, Wang SH, Ge HY, et al. The beneficial effects of the herbal medicine Free and Easy Wanderer Plus (FEWP) and fluoxetineon post-stroke depression. J Altern Complement Med, 2008, 14(7): 841-6.
8 Department of Neurology Branch of the Chinese Medical Association study group cerebrovascular ischemic stroke prevention compose a group of Chinese primary prevention of stroke Guide 2010. J Neurol, 2011, 44 (4): 282-8.
9 Psychiatry Branch of the Chinese Medical Association. Chinese Classification of Mental Disorders and diagnostic criteria (third edition). Shandong: Shandong Science and Technology Press, 2001, 60.
10 Zhang MY. Psychiatric Rating Scale Manual. Second edition, Changsha: Hunan Science and Technology Press, 1998, 16-27.
11 Miao HS, Zhu YL. Stroke rehabilitation assessment and treatment. Beijing: China Press, 1996, 9-22.
12 Turner A, Hambridge J, White J, et al. Depression screening in stroke: a comparison of alternative measures with the structured diagnostic interview for the diagnostic and statistical manual of mental disorders, fourth edition (majordepressive episode) as criterion standard. Stroke, 2012, 43(4): 1000-5.
13 Little K, Olsson CA, Whittle S, et al. Association between serotonin transporter genotype, brain structure and adolescent-onset majordepressive disorder: a longitudinal prospective study. Transl Psychiatry, 2014, 4: e445.
14 Lin Facai, Huang Dehong. Research Progression on Biological Mechanism of Post-stroke Depression. J Intl Transl Med, 2014, 2(2): 336-40.
15 Maffioletti E, Zanardini R, Gennarelli M, et al. Influence of clotting duration on brain-derived neurotrophic factor (BDNF) dosage in serum. Biotechniques, 2014, 57(3): 111-4.
16 Numakawa T, Richards M, Nakajima S, et al. The role of brain-derived neurotrophic factor in comorbid depression: possible linkage with steroid hormones, cytokines, and nutrition. Front Psychiatry, 2014, 5: 136.
17 Duman RS, Monteggia LM. A neurotrophic Model for Stress-Related Mood Disorders. Biol Psychiatry, 2006, 59(12): 1116-27.
18 Bachis A, Mallei A. Chronic antideprssant treatments increase basic fibroblast growth factor and fibroblast gronth factor-binding protein in neurons. Neuropharmacol, 2008, 55(7): 1114-20.
19 Molteni R, Calabrese F, Bedogni F, et al. Chronic treataaent with fluoxetine up-regulates cellular BDNF mRNA expression in rat dopaminergic regions. Nerropsychopharmacol, 2006, 9(3): 307-17.